Lung Cancer | Specialty

Trastuzumab Deruxtecan for HER2+ Non–Small Cell Lung Cancer

August 10th 2020

Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 Insertion

August 10th 2020

EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer

August 10th 2020

Chemotherapy-TKI Combinations in Metastatic EGFR+ Lung Cancer

August 10th 2020

TKI Combinations in Metastatic EGFR+ Lung Cancer

August 10th 2020

Role of Adjuvant Osimertinib in Early Stage NSCLC

August 10th 2020

ADAURA Trial; Early Stage Non–Small Cell Lung Cancer

August 10th 2020

CS1001 Plus Chemotherapy Shows Significant PFS Prolongation in Stage IV NSCLC

August 10th 2020

The anti–PD-L1 monoclonal antibody CS1001 in combination with platinum-based chemotherapy led to a significant improvement in progression-free survival when used as a frontline treatment for patients with stage IV squamous and nonsquamous non–small cell lung cancer.

ADCs Are Poised to Enter HER2-Mutant NSCLC Armamentarium

August 10th 2020

Paul A. Bunn, Jr, MD, discusses antibody-drug conjugates and how they are on the cusp of being introduced into the treatment paradigm for patients with HER2-mutant non–small cell lung cancer.

Nivolumab/Ipilimumab Demonstrates Durable OS Benefit in Malignant Pleural Mesothelioma

August 9th 2020

Nivolumab plus ipilimumab significantly improved overall survival versus chemotherapy in the first-line treatment of patients with unresectable malignant pleural mesothelioma.

Ensartinib Significantly Prolongs PFS Over Crizotinib in ALK+ NSCLC

August 8th 2020

Ensartinib showed a significant improvement in progression-free survival over crizotinib with a favorable safety profile in patients with ALK-positive non–small cell lung cancer.

Sintilimab/Pemetrexed Regimen Significantly Improves PFS in Advanced NSCLC

August 8th 2020

Sintilimab injection plus pemetrexed and platinum-based therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally advanced or metastatic nonsquamous non–small cell lung cancer.

Dr. Chiang on the Rationale for Chemoimmunotherapy in Lung Cancer

August 7th 2020

Anne Chiang, MD, PhD, discusses the rationale for combining immunotherapy with chemotherapy in lung cancer.

FDA Approves Guardant360 CDx Liquid Biopsy for Comprehensive Genomic Profiling Across All Solid Cancers

August 7th 2020

The FDA has approved Guardant360® CDx for comprehensive genomic profiling in patients with any solid malignant cancer.

Thoracic Leaders Examine Novel Treatment Options in Mesothelioma

August 7th 2020

In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in mesothelioma.

Multidisciplinary Collaboration Needed to Provide Cohesive Care in Advanced NSCLC

August 7th 2020

David R. Spigel, MD, discusses the Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC initiative, analyzes the survey data, and next steps for the research.

Dr. Kelly on Window-of-Opportunity Monotherapy Trials in Lung Cancer

August 7th 2020

Karen Kelly, MD, discusses the experimental window-of-opportunity studies with monotherapies in lung cancer.

Next-Generation TKIs Continue to Impress in ALK+ and ROS1+ NSCLC

August 6th 2020

Vamsidhar Velcheti, MD, discusses the current and emerging treatment options for patients with ALK- and ROS1-positive non–small cell lung cancer.

Experts Analyze Striking ASCO 2020 Data in Small Cell Lung Cancer

August 5th 2020

In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in extensive-stage SCLC and limited-stage SCLC.

Lorlatinib Significantly Improves PFS in Frontline ALK+ NSCLC

August 5th 2020

Lorlatinib significantly improved progression-free survival in treatment-naive patients with advanced ALK-positive non–small cell lung cancer versus crizotinib, meeting the primary end point of the phase 3 CROWN trial.